中文产业新闻评分71Chinese source
信达生物 IBI311 三期 RESTORE-3 达主要终点，突眼应答率 60.4%
新突破，又一“中国首个”原研药重磅新适应症来袭
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
新突破，又一“中国首个”原研药重磅新适应症来袭
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.